ACHV AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has been awarded the top rating for its value, but its dividend score is below 2. If the company starts distributing dividends, it may yield even better investment results.
ACHV Current Performance
0.72%
Achieve life sciences inc
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to ACHV
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
GUTS | Fractyl health inc | - | 2 | 2 | 2 | 1 | |
MURA | Mural oncology plc | - | 3 | 2 | - | 1 | |
ZVSA | Zyversa therapeutics inc | - | 2 | 2 | 1 | 1 | |
EXAS | Exact sciences corporation | 3 | 3 | 3 | 3 | 1 | |
AVBP | Arrivent biopharma inc | - | 4 | 3 | 3 | 1 |
- GUTS Fractyl health incValue -Trend 2Swing Trading 2Whale Interest 2Dividend 1See more
ACHV Profile
Achieve Life Sciences Inc. Achieve Life Sciences, Inc. is a late-stage clinical pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company's product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of action that is both agonistic and antagonistic. Cytisinicline is a partial agonist that binds with high affinity to the alpha-4 beta-2, nicotinic acetylcholine receptors in the brain. Through its dual-acting partial agonist/partial antagonist activity, cytisinicline helps reduce nicotine cravings, withdrawal symptoms and reward and satisfaction associated with smoking. It is developing cytisinicline as an aid to smoking cessation and treatment for nicotine addiction to address the limitations of both prescription drugs and of over the counter (OTC) products.